Announcing Fungible Storage Cluster with Support for VMware vSphere
7.6.2022 16:01:00 EEST | Business Wire | Press release
Fungible Inc., the dynamic composable infrastructure company, today announced a new release of Fungible Storage Cluster® (FSC) 4.1, providing support for VMware vSphere® environments requiring high-performance.
Virtual machines provide unparalleled flexibility in managing complex and changing compute environments. Workloads running in virtualized environments can have varied storage requirements. For demanding workloads, Fungible’s high-performance all-flash array based on NVMe/TCP is now certified for vSphere and available for VMware virtualized environments. The latest release (4.1) will now enable customers to experience the superior manageability of vSphere combined with the high performance of Fungible’s Storage Cluster.
"NVMe/TCP enables vSphere customers to accelerate their storage performance while leveraging existing investments and lowering complexity,” said Marc Fleischmann, Cloud CTO, VMware, “Through collaboration with innovative companies such as Fungible, VMware continues to build a world-class ecosystem of technology partners that offer our customers flexibility and choice to meet their business requirements.”
Customers can plug FSC storage into their ESXi servers with NVMe/TCP and get what appears to be local storage. The resulting performance is nearly identical to local storage even though it is a shared resource providing economic benefits to match the performance benefits.
“VMware vSphere is the virtualization infrastructure of choice for a variety of mission-critical, performance-sensitive workloads in the data center,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies at IDC. “As IT organizations deploy more workloads that require accelerated compute and storage, the use of composable, disaggregated infrastructure (CDI) like that available from Fungible will be deployed more often to enable the more efficient use of these types of resources in VMware environments. IDC expects that the CDI market overall will top $4.8 billion by 2025.”
“VMware has long led the drive to improve flexibility and utilization of data center infrastructure. Now with the latest release of our vSphere certified Fungible Storage Cluster, VMware users can further enhance their ability to tune demanding workloads to get the utmost performance and flexibility,” said Pradeep Sindhu, Co-Founder and CDO of Fungible. “Trade-offs of flexibility versus performance are no longer required. Pairing VMware with NVMe/TCP for storage access with our DPU-powered Storage Cluster allows VMware customers to address the performance requirements of today's modern applications.”
With FSC, vSphere users may also see storage cost savings since FSC’s erasure coding provides robust data protection which can be less expensive than traditional RF1 or RF2 replication. Additionally, Fungible’s composable data infrastructure provides flexibility to compose storage to meet current needs and recompose it to adapt to changing needs providing outstanding investment protection.
To learn more about the new FSC 4.1 and the VMware vSphere certification and how you can get more value and performance from your VMware vSphere resources click here or contact sales@fungible.com.
About Fungible:
Silicon Valley-based Fungible, the world’s premier dynamic composable infrastructure company, creates solutions to cloudify the world’s data centers by utilizing the Fungible DPU™ to connect CPUs, GPUs, and storage via NVMe/TCP over standard IP/Ethernet networks. Fungible aims to revolutionize the performance, economics, reliability and security of scale-out data centers. Visit Fungible to learn more. Follow us on Twitter and LinkedIn.
Fungible and Fungible FSC are registered trademarks of Fungible, Inc. VMware and vSphere are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005155/en/
Contact information
Jennifer Bell
Fungible, Inc.
(669) 292-5522
press@fungible.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom